Coloplast A/S - Transactions in connection with share buy-back programme, week 11

As mentioned in Announcement no. 02/2021 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The programme commenced on 22 February 2021 and is expected to end by 23 August 2021.

The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.

The following transactions have been executed during the period 15 – 19 March 2021:

Henceforth, Coloplast owns 3,094,847 treasury B shares of DKK 1 equal to 1.43% of the company’s total share capital.

An overview showing the transaction data for the period 15 – 19 March 2021 is enclosed.

Kind regards,
Investor Relations
Coloplast A/S
Tel. +45 4911 1800

For further information, please contact
  
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111

Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 /+45 4911 3376
Email: [email protected]

Aleksandra Dimovska
Sr. Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: [email protected]                                                                       

Press and the media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: [email protected]

Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917

Website
www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-03.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachments

• 22032021_Sharebuyback_week_11
• Transaction data_week_11

You May Also Be Interested In

• Intuitive Announces Board of Directors Elections and Retirements
• Dicello Levitt LLP Announces Investor Class Action Lawsuit Filed Against QuidelOrtho Corp. f/k/a Quidel Corp. (NASDAQ: QDEL) And Lead Plaintiff Deadline
• ROSEN, A TOP RANKED LAW FIRM, Encourages Plug Power Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PLUG